The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
New perspectives for targeting RAF kinase in human cancer
Open accessAbstract
The discovery that a subset of human tumours is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics. The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance. Beyond melanoma, current clinical RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumours or for tumours harbouring BRAF alterations other than the V600 mutation. Accumulated experimental and clinical evidence indicates that the complex biochemical mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumour resistance to them. Recently, a number of next-generation RAF inhibitors, with diverse structural and biochemical properties, have entered preclinical and clinical development. In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clinical resistance to these drugs. The recent elucidation of critical structural and biochemical aspects of RAF inhibitor action, combined with the availability of a number of structurally diverse RAF inhibitors currently in preclinical and clinical development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clinical contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [48]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Cited by
Sorted by citations
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Non–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 945
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kölch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 823
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Qin, T., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 406
Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy
Zheng, P., Zhou, C., Lu, L., Liu, B., & Ding, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02485-0 · Cited by 375
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Park, E., Rawson, S., Li, K., Kim, B.-W., Ficarro, S. B., Pino, G. L. G., Sharif, H., Marto, J. A., Jeon, H., & Eck, M. J. (2019) · Nature · doi:10.1038/s41586-019-1660-y · Cited by 309
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 289
Initiation and amplification of SnRK2 activation in abscisic acid signaling
Lin, Z., Li, Y., Wang, Y., Liu, X., Ma, L., Zhang, Z., Mu, C., Zhang, Y., Li, P., Xie, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22812-x · Cited by 280
Codon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Édouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 248
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Heinzerling, L., Eigentler, T., Fluck, M., Hassel, J. C., Heller-Schenck, D., Leipe, J., Pauschinger, M., Vogel, A., Zimmer, L., & Gutzmer, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000491 · Cited by 242
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Arter, C., Trask, L., Ward, S., Yeoh, S., & Bayliss, R. W. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102247 · Cited by 238
Ahmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.013 · Cited by 214
Self-citationImidazoles as Potential Anticancer Agents: An Update on Recent Studies
Sharma, P., LaRosa, C., Antwi, J., Govindarajan, R., & Werbovetz, K. A. (2021) · Molecules · doi:10.3390/molecules26144213 · Cited by 220
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0274-5 · Cited by 195
The journey from melanocytes to melanoma
Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 211
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 199
Targeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 195
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., Maddalena, P., et al. (2020) · Cancers · doi:10.3390/cancers12071823 · Cited by 192
Development of encorafenib for BRAF-mutated advanced melanoma
Koelblinger, P., Olaf, T., & Dummer, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000426 · Cited by 191
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
Chen, C., Wu, M.-Y., Ng, C. Y., Lu, C., Wu, J., Kao, P., Yang, C., Peng, M., Huang, C., Chang, W.-C., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s163391 · Cited by 164
MEK drives BRAF activation through allosteric control of KSR proteins
Lavoie, H., Sahmi, M., Maisonneuve, P., Marullo, S. A., Thevakumaran, N., Jin, T., Kurinov, I. V., Sicheri, F., & Therrien, M. (2018) · Nature · doi:10.1038/nature25478 · Cited by 152
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Tang, X., Tan, L., Shi, K., Peng, J., Xiao, Y., Li, W., Chen, L., Yang, Q., & Qian, Z. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.011 · Cited by 147
Prospects for pharmacological targeting of pseudokinases
Kung, J. E., & Jura, N. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0018-3 · Cited by 144
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Self-citationThe Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 143
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R. D., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Seventer, E. E. V., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 130
Combatting Mucosal Melanoma: Recent Advances and Future Perspectives
Tyrrell, H. E. J., & Payne, M. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0003 · Cited by 123
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 133
Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
Botton, T., Talevich, E., Mishra, V. K., Zhang, T., Shain, A. H., Berquet, C., Gagnon, A., Judson, R. L., Ballotti, R., Ribas, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.009 · Cited by 113
Engineered prime editors with PAM flexibility
Kweon, J., Yoon, J.-K., Jang, A.-H., Shin, H. R., See, J.-E., Jang, G., Kim, J., & Kim, Y. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.022 · Cited by 111
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 111
Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants
Wegert, J., Vokuhl, C., Collord, G., Velasco‐Herrera, M. D. C., Farndon, S. J., Guzzo, C., Jørgensen, M., Anderson, J., Slater, O., Duncan, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04650-6 · Cited by 105
Current Insights of BRAF Inhibitors in Cancer
Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 103
Self-citationSchirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0311 · Cited by 102
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 107
Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96
Inhibition of RAF dimers: it takes two to tango
Cook, F. A., & Cook, S. J. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200485 · Cited by 90
Genetic Code Expansion: Recent Developments and Emerging Applications
Huang, Y., Zhang, P., Wang, H., Chen, Y., Liu, T., & Luo, X. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00216 · Cited by 109
RNA sequencing for research and diagnostics in clinical oncology
Buzdin, A. A., Sorokin, M., Garazha, A., Glusker, A., Aleshin, A., Poddubskaya, E. V., Sekacheva, M. I., Kim, E. L., Гайфуллин, Н., Giese, A., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.010 · Cited by 94
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A., & Lebbé, C. (2019) · Cancers · doi:10.3390/cancers11081133 · Cited by 89
BRAF in malignant melanoma progression and metastasis: potentials and challenges.
Alqathama, A. A. (2020) · PubMed Central · Cited by 86
Inhibitors of BRAF dimers using an allosteric site
Cotto-Rios, X. M., Agianian, B., Gitego, N., Zacharioudakis, E., Giricz, O., Wu, Y., Zou, Y., Verma, A. K., Poulikakos, P. I., & Gavathiotis, E. (2020) · Nature Communications · doi:10.1038/s41467-020-18123-2 · Cited by 87
Self-citationTRIM24-RIP3 axis perturbation accelerates osteoarthritis pathogenesis
Jeon, J., Noh, H.-J., Lee, H., Park, H.-H., Ha, Y., Park, S. H., Lee, H., Kim, S.-J., Kang, H. C., Eyun, S., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217904 · Cited by 83
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Klomp, J. E., Diehl, J. N., Klomp, J. A., Edwards, A. C., Yang, R., Morales, A. J., Taylor, K. E., Drizyte-Miller, K., Bryant, K. L., Schaefer, A., et al. (2024) · Science · doi:10.1126/science.adk0850 · Cited by 83
Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
Ma, Y., Xia, R., Ma, X., Judson‐Torres, R. L., & Zeng, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702287 · Cited by 88
Yang, L., Shen, C., Estrada‐Bernal, A., Robb, R. N., Chatterjee, M., Sebastian, N., Webb, A., Mo, X. M., Chen, W., Krishnan, S., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab871 · Cited by 80
Targeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor
Christensen, J. G., Olson, P., Briere, T., Wiel, C., & Bergö, M. O. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13057 · Cited by 77
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
Oldrini, B., Curiel‐García, Á., Marques, C., Matía, V., Uluçkan, Ö., Graña‐Castro, O., Torres-Ruiz, R., Rodríguez, S., Huse, J. T., & Squatrito, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03731-w · Cited by 78
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
Mo, X., Niu, Q., Ivanov, A. A., Tsang, Y. H., Tang, C., Shu, C., Li, Q., Qian, K., Wahafu, A., Doyle, S. P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.014 · Cited by 73
RAF kinase dimerization: implications for drug discovery and clinical outcomes
Brummer, T., & McInnes, C. (2020) · Oncogene · doi:10.1038/s41388-020-1263-y · Cited by 72
Signaling from RAS to RAF: The Molecules and Their Mechanisms
Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Wei, J., Hu, J., Wang, L., Xie, L., Jin, M. S., Chen, X., Liu, J., & Jin, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01528 · Cited by 67
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
Farnaby, W., Koegl, M., McConnell, D. B., & Ciulli, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.009 · Cited by 66
Discovery of Selective Small Molecule Degraders of BRAF-V600E
Han, X., Chen, L., Wei, Y., Yu, W., Chen, Y., Zhang, C., Jiao, B., Shi, T., Sun, L., Zhang, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02083 · Cited by 64
Urea-based anticancer agents. Exploring 100-years of research with an eye to the future
Listro, R., Rossino, G., Piaggi, F., Sonekan, F. F., Rossi, D., Linciano, P., & Collina, S. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.995351 · Cited by 61
Robb, R. N., Yang, L., Shen, C., Wolfe, A. R., Webb, A., Zhang, X., Vedaie, M., Saji, M., Jhiang, S. M., Ringel, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3625 · Cited by 60
Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
Robinson, M. H., Vasquez, J. C., Kaushal, A., MacDonald, T. J., Vega, J. E. V., Schniederjan, M., & Dhodapkar, K. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001066 · Cited by 60
Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
He, M., Lv, W., & Rao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685106 · Cited by 63
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
Gunderwala, A. Y., Nimbvikar, A., Cope, N. J., Li, Z., & Wang, Z. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00191 · Cited by 57
Cancer vaccines: Targeting KRAS-driven cancers
Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 58
Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics
Abe, I., & Lam, A. K.-Y. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01019-9 · Cited by 57
Byrne, D. P., Li, Y., Ngamlert, P., Ramakrishnan, K., Eyers, C. E., Wells, C. I., Drewry, D. H., Zuercher, W. J., Berry, N. G., Fernig, D. G., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180266 · Cited by 54
Tripathi, V. C., Satish, S., Horam, S., Raj, S., lal, A., Arockiaraj, J., Pasupuleti, M., & Dikshit, D. K. (2018) · Polar Science · doi:10.1016/j.polar.2018.04.006 · Cited by 54
Sun, J. X., Zager, J., & Eroglu, Z. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171693 · Cited by 47
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54
Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 58
The mechanism of Raf activation through dimerization
Zhang, M., Maloney, R., Jang, H., & Nussinov, R. (2021) · Chemical Science · doi:10.1039/d1sc03444h · Cited by 52
Fu, L., Chen, S., He, G., Chen, Y., & Liu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01244 · Cited by 53
Ryan, M. B., Quade, B., Schenk, N., Fang, Z., Zingg, M., Cohen, S. E., Swalm, B. M., Li, C., Özen, A., Ye, C., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0139 · Cited by 51
40 Years of RAS—A Historic Overview
Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 57
B-Raf autoinhibition in the presence and absence of 14-3-3
Zhang, M., Jang, H., Li, Z., Sacks, D. B., & Nussinov, R. (2021) · Structure · doi:10.1016/j.str.2021.02.005 · Cited by 53
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Vido, M. J., Le, K., Hartsough, E. J., & Aplin, A. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.049 · Cited by 55
Dankner, M., Wang, Y., Fazelzad, R., Johnson, B., Nebhan, C. A., Dagogo‐Jack, I., Myall, N. J., Richtig, G., Bracht, J. W. P., Gerlinger, M., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00107 · Cited by 51
Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 52
Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1
Shaw, J., Dale, I. L., HEMSLEY, P. E., Leach, L. J., Shalaly, N. D., Orme, J. P., Talbot, V. A., Narvaez, A. J., Biśta, M., Molina, D. M., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218813332 · Cited by 47
Countering TRAIL Resistance in Melanoma
Eberle, J. (2019) · Cancers · doi:10.3390/cancers11050656 · Cited by 46
Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022
Singh, A. K., Sonawane, P., Kumar, A., Singh, H., Naumovich, V., Pathak, P., Grishina, M., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c00332 · Cited by 47
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 51
tRNA Modification and Cancer: Potential for Therapeutic Prevention and Intervention
Endres, L., Fasullo, M., & Rose, R. E. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0404 · Cited by 46
Tan, J., Liu, R., Zhu, G., Umbricht, C. B., & Xing, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004707117 · Cited by 46
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Wu, P., Hong, S., Starenki, D., Oshima, K., Shao, H., Gestwicki, J. E., Tsai, S., & Park, J. (2020) · Oncogene · doi:10.1038/s41388-020-1285-5 · Cited by 44
Ghousein, A., Mosca, N., Cartier, F., Charpentier, J., Dupuy, J., Raymond, A., Bioulac‐Sage, P., & Grosset, C. F. (2019) · Liver International · doi:10.1111/liv.14276 · Cited by 43
Zhao, J., & Luo, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095158 · Cited by 43
TINCR facilitates non-small cell lung cancer progression through BRAF-activated MAPK pathway
Zhu, Z., & He, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.059 · Cited by 42
Metadata
- Authors
- Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Cancer
- Published
- 2017-10-06
- Volume
- 17
- Issue
- 11
- Pages
- 676-691
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC6000833
- OpenAlex
- W2762842128
- Cited by
- 404
- References
- 125
- Citations by year
- 2026: 24 · 2025: 37 · 2024: 48 · 2023: 48 · 2022: 46 · 2021: 52 · 2020: 51 · 2019: 58 · 2018: 37 · 2017: 2
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Dermatology Foundation
- Melanoma Research Alliance
- Sidney Kimmel Foundation for Cancer Research
- Sidney Kimmel Foundation
- Pershing Square Sohn Cancer Research Alliance
- National Institutes of Health
- National Cancer Institute (R01CA178394, R01CA204314)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Raf kinase, BRAF mutation, RAF inhibitors, vemurafenib, dabrafenib, melanoma, BRAF V600E mutation, drug resistance, colorectal cancer, thyroid cancer, inhibitor design
- MeSH terms
- Humans, Neoplasms, Protein Kinase Inhibitors, raf Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
